Key result
Atorvastatin reduces LMCA inflammation more in high-risk plaques than non-high-risk plaques.
RCT
Blinded outcome assessment (CTA readers blinded to PET findings)
Answers are grounded in this paper and cite their sources.
BACKGROUND: Nonobstructive coronary plaques manifesting high-risk morphology (HRM) associate with an increased risk of adverse clinical cardiovascular events. We sought to test the hypothesis that statins have a greater anti-inflammatory effect within coronary plaques containing HRM. METHODS AND RESULTS: F-fluorodeoxyglucose uptake, expressed as target-to-background ratio) was assessed in the left main coronary artery (LMCA). While blinded to the PET findings, contrast-enhanced computed tomographic angiography was performed to characterize the presence of HRM (defined as noncalcified or partially calcified plaques) in the LMCA. Arterial inflammation (target-to-background ratio) was higher in LMCA segments with HRM than those without HRM (mean±SEM: 1.95±0.43 versus 1.67±0.32 for LMCA with versus without HRM, respectively; P=0.04). Moreover, atorvastatin treatment for 12 weeks reduced target-to-background ratio more in LMCA segments with HRM than those without HRM (12 week-baseline Δtarget-to-background ratio [95% confidence interval]: -0.18 [-0.35 to -0.004] versus 0.09 [-0.06 to 0.26]; P=0.02). Furthermore, this relationship between coronary plaque morphology and change in LMCA inflammatory activity remained significant after adjusting for baseline low-density lipoprotein and statin dose (β=-0.27; P=0.038). CONCLUSIONS: In this first study to evaluate the impact of statins on coronary inflammation, we observed that the anti-inflammatory impact of statins is substantially greater within coronary plaques that contain HRM features. These findings suggest an additional mechanism by which statins disproportionately benefit individuals with more advanced atherosclerotic disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00703261.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2016) conducted an RCT in Coronary atherosclerosis / nonobstructive coronary plaques with high-risk morphology. Atorvastatin in LMCA plaques with high-risk morphology (HRM) vs. Atorvastatin in LMCA plaques without high-risk morphology (HRM) was evaluated on 12-week change from baseline in left main coronary artery F-fluorodeoxyglucose uptake (Δtarget-to-background ratio) (β -0.27, p=0.02). Atorvastatin for 12 weeks reduced LMCA arterial inflammation (ΔTBR) more in plaques with high-risk morphology than without.
Synapse has enriched 10 related papers. Consider them for comparative context: